CALT

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
Ken GriffinCitadel Advisors $-581.0K ExitQ3 2024 $581k -- --
Ken GriffinCitadel Advisors $-581.0K ExitQ3 2024 $581k -- --

News

defenseworld.netFinancial Survey: MindWalk (NASDAQ:HYFT) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT)defenseworld.netMar 10

Trade CALT

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ) operates as a clinical-stage biopharmaceutical entity, committed to identifying, advancing, and commercializing therapeutic products. Its primary focus lies in developing treatments for rare (orphan) conditions, with a particular emphasis on disorders impacting the renal and hepatic systems. The company markets Nefecon, an orally administered formulation of budesonide, which functions as an immunosuppressive agent designed to address immunoglobulin A nephropathy, an autoimmune kidney disease. Its flagship investigational product is Setanaxib, a NOX inhibitor. Setanaxib is currently undergoing Phase 2b/3 clinical trials for primary biliary cholangitis. Furthermore, it is being evaluated in Phase 2 studies for various other indications, including squamous cell carcinoma of the head and neck, idiopathic pulmonary fibrosis, and type 1 diabetic kidney disease. Calliditas's pipeline also includes Budenofalk 3 mg oral capsules, which are under development for the treatment of autoimmune hepatitis. The company was established in 2004 and has its corporate headquarters located in Stockholm, Sweden.

CEO: Renee Aguiar-Lucander
IPO Date: Jun 5, 2020

Market Data

Open: $40.00
High: $43.00
Low: $40.00
Volume: 9.8K
52W High: $43.00
52W Low: $15.25

Valuation

Market Cap: $2.1B
Enterprise Value: $11B

Financials

Free Cash Flow: $-447M
Revenue: $1.2B
Net Income: $-466M
Cash: $974M
Debt: $979M

Events

EarningsNov 11

EPS est. -0.22 · actual -0.58